News for Adaptive Biotechnologies Corp (1HM.DE)

On Tuesday, Cathie Wood-led Ark Invest made significant trades involving Tesla Inc. and Coinbase Global Inc. . These trades reflect Ark’s strategic positioning amid ongoing market developments.

On June 18, 2025, Adaptive Biotechnologies (ADPT) received a significant boost as Craig-Hallum initiated coverage on the stock with a ”œBuy” rating. Analyst

Adaptive Biotechnologies (ADPT) has been given a "Buy" rating by Craig-Hallum, which also set a price target of $15. As the dominant player in the $1.8 billion

Craig-Hallum has commenced coverage on Adaptive Biotechnologies (ADPT), assigning a Buy rating to the stock. Analyst John Wilkin has set a target price of $15,

Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocketâ„¢, today announced the appointment of Chad Cohen, former Chief Financial Officer of Zillow Grou

June 3 - Cathie Wood's Ark Invest sold 1,594 shares of Tesla Inc (TSLA) through its ARK Innovation ETF (ARKK), offloading a position worth $546,247, according t

On Monday, Cathie Wood-led Ark Invest sold shares of Tesla and Palantir, amidst competition and data misuse concerns. Ark also made significant trades in other companies, such as eToro and Illumina.

Adaptive Biotechnologies (ADPT) is set to highlight its clonoSEQ test, which leverages next-generation sequencing for measurable residual disease (MRD) assessme

ARK Invest, led by Cathie Wood, made significant trades involving Tesla and Tempus AI amid insider sales and short seller scrutiny. $5.6 million in Tesla shares sold, $13.36 million in Tempus AI shares bought on Wednesday May 28, 2025.

On March 31, 2025, a notable transaction was executed by the esteemed market expert Catherine Wood (Trades, Portfolio), founder of ARK Investment Management. Th

On Thursday, Cathie Wood-led Ark Invest made significant moves in the stock market, focusing on Shopify Inc. (NASDAQ:SHOP), Palantir Technologies Inc. (NASDAQ:PLTR), and Block I

On May 6, 2025, Piper Sandler analyst David Westenberg announced a revised price target for Adaptive Biotechnologies (ADPT). The price target was increased from

Piper Sandler has adjusted its price target for Adaptive Biotechnologies (ADPT), elevating it from $11 to $13 while maintaining an Overweight rating on the stoc

Morgan Stanley has recently updated its price target for Adaptive Biotechnologies (ADPT), raising it from $7.00 to $9.00 per share. This adjustment represents a

Morgan Stanley has revised its price target for Adaptive Biotechnologies (ADPT), raising it to $9 from the previous $7. The investment firm maintained its Equal

\nAdaptive Biotechnologies Corp (ADPT) showcases a robust immune-driven medicine platform with FDA-authorized diagnostic products.Despite a strong product portfo

Adaptive Biotechnologies (ADPT) reported impressive financial results for the first quarter, with revenue reaching $52.44 million, significantly surpassing the

On Wednesday, April 23, 2025, Cathie Wood of Ark Invest purchased more stock of AMD and Nvidia amid looming US chip curbs against China.

Summary Adaptive Biotechnologies Corp (ADPT), a commercial-stage biotechnology company focused on leveraging the adaptive immune system for disease diagnosis an